Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Outsourcing

- PMLiVE

Takeda to acquire Nimbus’ TYK2 inhibitor in deal worth $6bn

NDI-034858 is under evaluation for the treatment of multiple autoimmune diseases

- PMLiVE

Takeda’s dengue vaccine receives EC approval

The decision follows a positive recommendation for Qdenga from the CHMP in October

- PMLiVE

Takeda’s Exkivity receives NICE recommendation for rare form of lung cancer

Patients with EGFR Exon20ins+ NSCLC make up approximately 2% of NSCLC cases

- PMLiVE

Takeda’s dengue vaccine candidate recommended for approval by CHMP

Dengue disease causes around 390 million infections and 500,000 hospitalisations each year

- PMLiVE

UK Government announces £50m research boost to tackle health inequalities

The investment will be given to 13 local authorities across the UK, from Aberdeen to Plymouth

- PMLiVE

Moderna to launch Innovation and Technology Center in the UK

With support from the UK government, the manufacturing facility is expected to produce up to 250 million doses annually

- PMLiVE

Takeda and Daiichi Sankyo collaborate to create wearable device

Takeda and Daiichi Sankyo have announced that they will work on a new research project, along with Tohoku University and MICIN, a digital health and telemedicine company, to develop a...

- PMLiVE

Novartis restructures organisation to support growth and innovation

The new operational structure will involve integrating pharmaceuticals and oncology business units into an Innovative Medicines business

- PMLiVE

UK government announce £260m to boost healthcare research and manufacturing

This investment will help the NHS deliver new life-saving treatments to patients more efficiently and will help to support more diverse and inclusive clinical research

Takeda agrees on $2bn deal with Code Bio to expand its gene therapy programmes

The pharma company will gain opt-in rights for four rare diseases candidates

- PMLiVE

FDA rejects Takeda’s Eohilia after delays

After more than a year on ‘priority review’, the FDA has said it cannot approve Takeda’s budesonide oral suspension without a further clinical study

- PMLiVE

Merck’s Keytruda gains two more approvals in Japan

New approvals in breast and colorectal cancer take the number of indication for the immunotherapy mega-blockbuster to 15 in Japan

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links